CBD Gummies And Warfarin

CBDISTILLERY

Buy CBD Oil Online

A case of an 85-year-old patient with concurrent use of warfarin and medical cannabis containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is described. Warfarin continues to be a cornerstone of anticoagulation treatment despite the recent addition of FDA-approved anticoagulant agents. It is well known that warfarin has numerous drug interactions; however, much remains unknown about its interaction with THC and CBD. A literature review was conducted to identify documented cases of possible interactions between cannabis and warfarin. The case reports we identified noted that cannabis may potentially increase warfarin’s effect. Therefore, we aimed to determine why an effect was not seen on our patient’s warfarin dose despite daily use of medical cannabis. This case report describes an 85-year-old patient who despite starting an oromucosal medical cannabis regimen of THC and CBD (which provided 0.3 mg of THC and 5.3 mg CBD once daily and an additional 0.625 mg of THC and 0.625 mg CBD once daily as needed) had minimal INR fluctuations from October 2018 to September 2019. Despite the introduction and use of medical cannabis therapy, with both THC and CBD components, an elderly patient with concurrent warfarin use did not see major INR fluctuations, in contrast to published literature. The potential for warfarin and THC/CBD interactions may be dependent on route of administration and dose of the cannabis product. Warfarin is an anticoagulant that helps to prevent blood clot formation and is used to treat deep vein thrombosis

Case report: Medical cannabis—warfarin drug-drug interaction

A case of an 85-year-old patient with concurrent use of warfarin and medical cannabis containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is described. Warfarin continues to be a cornerstone of anticoagulation treatment despite the recent addition of FDA-approved anticoagulant agents. It is well known that warfarin has numerous drug interactions; however, much remains unknown about its interaction with THC and CBD. A literature review was conducted to identify documented cases of possible interactions between cannabis and warfarin. The case reports we identified noted that cannabis may potentially increase warfarin’s effect. Therefore, we aimed to determine why an effect was not seen on our patient’s warfarin dose despite daily use of medical cannabis.

This case report describes an 85-year-old patient who despite starting an oromucosal medical cannabis regimen of THC and CBD (which provided 0.3 mg of THC and 5.3 mg CBD once daily and an additional 0.625 mg of THC and 0.625 mg CBD once daily as needed) had minimal INR fluctuations from October 2018 to September 2019.

Conclusion

Despite the introduction and use of medical cannabis therapy, with both THC and CBD components, an elderly patient with concurrent warfarin use did not see major INR fluctuations, in contrast to published literature. The potential for warfarin and THC/CBD interactions may be dependent on route of administration and dose of the cannabis product.

Introduction

Warfarin is a widely used agent in the USA for the prevention of thrombotic complications related to atrial fibrillation and venous thromboembolism (US Department of Health and Human Services, Office of Disease Prevention and Health Promotion 2014). Due to warfarin’s narrow therapeutic index, it is paramount that health care professionals are aware of agents that may interact with it. Legalization of cannabis for both medical and recreational purposes has greatly increased its use throughout the USA. The increased use in the older population is notable, as older people are likely to be on chronic medications which may interact with cannabis, including warfarin (Han et al. 2017; Lloyd and Striley 2018). Medical cannabis is commonly used to treat chronic pain of various origins. Evidence suggests receptors in the endocannabinoid system are heavily involved in pain regulation (Lloyd and Striley 2018; Health Canada 2018). Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) interact with cannabinoid receptor sub-type 1 (CB1) and cannabinoid receptor sub-type 2 (CB2) receptors to produce analgesia. THC is a partial agonist at CB1&2, while CBD acts indirectly on these receptors and modulates THC’s effects (MacCallum and Russo 2018). Based on THC and CBD’s ability to inhibit cytochrome P450 enzymes CYP3A4 and CYP2C9, medical cannabis is purported to inhibit the metabolism of warfarin, increasing its anticoagulant effects. This report describes the case of an older patient on warfarin who started medical cannabis for pain management. In contrast to published literature showing INR elevation with concomitant warfarin and cannabis product use, there was no change observed in his warfarin dosing requirement despite the patient’s consistent daily use of medical cannabis for nearly a year.

Patient case

This case report describes an older-adult patient who was maintained on warfarin therapy and later started treatment with medical cannabis for pain management. This patient, an 85-year-old, 82.55 kg male, was enrolled in our institution’s anticoagulation clinic for the management of warfarin for secondary stroke prevention in the setting of atrial fibrillation/flutter since 2012. The patient’s past medical history was significant for coronary artery disease, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, stroke, and chronic lower back pain. The patient reported to our anticoagulation clinic pharmacists that he began taking medical cannabis in November 2018 to help with his chronic lower back pain. In the preceding 2 years, prior to medical cannabis use, the patient had been on a stable dose of warfarin at 22.5 mg/week with minimal deviations. The patient’s weekly warfarin doses, INR levels, and medical cannabis use are described in Table 1. In addition to warfarin, his other home medications included albuterol, amiodarone, amlodipine, atorvastatin, docusate, finasteride, folic acid, gabapentin, isosorbide mononitrate, metoprolol tartrate, and sertraline. The patient reported no relevant medication or dietary changes over the course of his concomitant treatment with warfarin and medical cannabis.

The patient reported, and his medical cannabis dispensary confirmed that he was taking a combination of two oil cannabis products administered via the oromucosal route. One of these products he self-administered once daily, every day, the other product he used as needed. His once daily product was used for basal pain control and delivered 0.3 mg of THC and 5.3 mg of CBD once daily. His product for breakthrough pain was used once daily as needed and delivered 0.625 mg of THC and 0.625 mg of CBD. Despite daily use of medical cannabis for nearly a year, his warfarin requirements remained unchanged (see Table 1). The patient’s INRs were checked consistently while the patient was taking this medical cannabis product, at intervals according to our facility’s warfarin monitoring algorithm. Further inquiry with the patient’s dispensary revealed that the patient’s medical cannabis regimen was designed to provide him with “micro-doses” of CBD and THC. This practice is based on the theory that small doses may provide minor activation of cannabinoid 1 and 2 receptors and allow the user’s body to adapt to the drug. Micro-dosing appears to be a medical cannabis industry term, as we were unable to find any published, peer-reviewed references using this term.

See also  CBD Oil And Lyme Disease

Discussion

In our patient case, treatment with medical cannabis did not significantly impact warfarin therapy and INR levels remained stable. This observed effect is contrary to other reports that suggest cannabis may interact with warfarin therapy and lead to increased INR levels (Damkier et al. 2019; Yamreudeewong et al. 2009; Hsu and Painter 2019; Grayson et al. 2017; Brown et al. 2021). THC is the primary psychoactive compound present in cannabis. CBD, another major cannabinoid compound, is believed to contribute to cannabis’ therapeutic effects (Health Canada 2018; Pertwee 2014). Available dosage forms for cannabis include capsules, oils, tinctures, lozenges, edibles, topicals, rectal suppositories, and oromucosal spray (MacCallum and Russo 2018). Medical cannabis products may be prepared for oral, oromucosal, nasal, transdermal, and rectal administration (MacCallum and Russo 2018). Inhalation of the aerosols from vaporization (i.e., “vaping”) or combustion (i.e., “smoking”) are also common methods of administration (MacCallum and Russo 2018).

Our search revealed 5 relevant articles describing INR elevations in patients on warfarin who were also using cannabis products. Two case reports revealed INR elevation with smoked cannabis for recreational use (Damkier et al. 2019; Yamreudeewong et al. 2009). A third case report also showed INR elevation with primarily edible cannabis and occasional smoked cannabis use that was prescribed for anxiety and attention deficit hyperactivity disorder (Hsu and Painter 2019). A fourth case report describes INR elevation in a patient on warfarin receiving two medical cannabis sublingual oil products at a total daily dose of 14.7 mg THC and 10.3 mg CBD (Brown et al. 2021).

In addition to previously published case reports, information on the FDA-approved drug, CBD oral solution (Epidiolex®), may be helpful in predicting the effects medical cannabis may have on metabolism of concurrent drugs. The manufacturer recommends considering dose reductions of CYP2C9 substrates, such as warfarin, in patients treated with CBD oral solution. The fifth case report found that CBD oral solution, administered at a dose starting at 5 mg/kg/day and titrated up to 35 mg/kg/day, did impact warfarin therapy resulting in an elevated INR (Grayson et al. 2017).

Our patient’s medical cannabis regimen delivered between 0.064 and 0.072 mg/kg/day of CBD and did not elevate his INR. In vitro studies suggest THC and CBD both are capable of inhibiting CYP2C9 and may increase warfarin’s effect in a dose-dependent manner (Health Canada 2018; Yamaori et al. 2012). We theorize that the THC and CBD amounts our patient was exposed to were lower than the amounts required to inhibit CYP2C9’s warfarin metabolism. Our theory is supported by the low ratios of the estimated maximum serum concentrations (Cmax) of CBD and THC and the in vitro inhibitory concentrations (Ki). According to Kiyomi et al., a Cmax/Ki ratio < 0.1 is considered to have a low risk of causing a clinically observed drug-drug interaction (Kiyomi et al. 2004). The Cmax/Ki ratios for CBD and THC for this patient were 4.9 × 10 −4 and 7.3 × 10 −4 , respectively. Because we did not have the patient’s serum CBD or THC levels, we estimated CBD and THC Cmax by using dosing data reported by Miller et al. to find the best-fit line and its equation for CBD (Miller et al. 2018). Table 2 shows the CBD doses, Cmax, and the equation and R 2 value for the best-fit trend line. Using the estimated Cmax, 0.87 ng/mL (by entering the patient’s daily CBD dose into the best-fit line equation), the Ki determined by Yamaori (5.6 μM), and CBD’s molecular weight (314.47 ng/nanomoles), we calculated the ratio as follows:

$$_>/_>=0.87;mathrm/mathrmdiv 5.6 upmu mathrm/mathrm=left(0.87;mathrm/mathrmtimes 1000;mathrmright)div 5.6 upmu mathrm=left(870;mathrmtimes 1 mathrmdiv 314.47;mathrmright)div 5.6 upmu mathrm=2.77 mathrmmathrmdiv 5.6 upmu mathrm=2.77times ^ upmu mathrmdiv 5.6 upmu mathrm=4.9times ^$$

Table 2 Cannabidiol (CBD) doses, maximum serum concentrations, and best-fit trend line to estimate our patient’s maximum serum concentration

To estimate our patient’s THC Cmax, we utilized the Cmax and THC dosing data reported by Poyatos et al. to find the best-fit line and its equation (Poyatos et al. 2020). Table 3 shows the THC doses, Cmax, and the equation and R 2 value for the best-fit trend line. Using the estimated Cmax, 0.35 ng/mL, the Ki determined by Yamaori (1.5 μM), and THC’s molecular weight (314.45 ng/nanomoles), we calculated the ratio as follows:

$$_>/_>=0.35;mathrm/mathrmdiv 1.5 upmu mathrm/mathrm=left(0.35;mathrm/mathrmtimes mathrm;mathrmright)div 1.5 upmu mathrm=left(350;mathrmtimes mathrmdiv 314.45;mathrmright)div 1.5 upmu mathrm=1.1 mathrmdiv 1.5 upmu mathrm=1.1times ^ upmu mathrmdiv 1.5 upmu mathrm=7.3times ^$$

Table 3 Tetrahydrocannabinol (THC) doses, maximum serum concentrations and best-fit trend line to estimate our patient’s maximum serum concentration

While our estimated Cmax/Ki ratios of CBD and THC were much lower than 0.1, we want to point out that the Cmax/Ki ratio of THC in the fourth case report by Brown et al. was 0.012, also less than 0.1, but 100 times closer to the 0.1 ratio. Despite achieving a Cmax/Ki ratio of less than 0.1, Brown and colleagues observed interaction between medical cannabis and warfarin (Brown et al. 2021). These conflicting findings confirm the need for additional study of the estimated plasma doses achieved with medical cannabis products and the mechanism by which medical cannabis interacts with other medications.

See also  Peanut Butter Flavored CBD Oil For Dogs

THC is metabolized by CYP3A4, CYP2C19, and CYP2C9, while CBD is metabolized by CYP3A4, CYP2C19, and potentially by CYP2C9 and CYP1A1/1A2 (Health Canada 2018).Though information about how THC and CBD interact with CYP enzymes varies in the literature, both THC and CBD appear to inhibit CYP3A4, CYP2C19, CYP2C9, and CYP1A1/1A2 (Health Canada 2018; Yamaori et al. 2012). Therefore, it is important that the health care professional monitors for a medical cannabis product’s potential to interact with drugs metabolized by these enzymes, which would include warfarin. Warfarin is comprised of a racemic mixture of S- and R-warfarin, and the S-enantiomer is the more potent of the two. CYP2C9 is responsible for metabolizing the more potent S-warfarin. Therefore, interactions affecting CYP2C9 metabolism are expected to have a greater effect on warfarin’s anticoagulant effects, as measured by INR levels, and the need for warfarin dosage adjustments to maintain therapeutic INR levels. Table 4 summarizes enzymes involved in warfarin, THC, and CBD metabolism.

Table 4 CBD and THC interactions with enzymes associated with warfarin metabolism (Health Canada 2018; Yamaori et al. 2012; Anderson and Chan 2016; Sachse-Seeboth et al. 2009)

Numerous variables affect the likelihood of cannabinoids, such as THC and CBD, to interact with CYP450 enzymes, including the route of administration, product formulation, pharmacogenetics, and dosage (Health Canada 2018). Cannabis products may be administered via multiple different routes, including smoking, vaping, and ingestion, and each mode of administration has a unique effect on CYP enzymes and consequently its potential to interact with drugs. For example, smoke from combustion of cannabis contains polyaromatic hydrocarbons which are capable of inducing CYP1A1/2. This could theoretically increase metabolism of R-warfarin leading to decreased INR levels. Sublingual and buccal routes are known to avoid first-pass metabolism by the liver and thus may have less potential for interactions with CYP enzymes. However, in the fourth case report, the authors describe a patient using oromucosal THC products which led to a supratherapeutic INR, suggesting that oromucosal routes do not completely avoid hepatic metabolic pathways (Brown et al. 2021). Despite the use of oromucosal medical cannabis products in our patient, we did not see any changes in INR levels that were suggestive of changes in warfarin metabolism. Therefore, we believe the THC and CBD doses consumed by our patient were below the threshold needed to produce meaningful inhibition of CYP2C9 (Health Canada 2018; MacCallum and Russo 2018; Kaminsky and Zhang 1997).

Finally, we considered the possibility of CYP activity decline as a factor for not observing an interaction between medical cannabis and warfarin. CYP-mediated phase I reactions have been shown to decline with advancing age, but phase II reactions appear to remain intact (Klotz 2009). We are unable to comment on the impact of reduced phase I metabolism on our observed findings. The link between declining CYP-mediated phase I reactions and the risk for medical cannabis-drug interactions may warrant additional investigation.

When evaluating the drug-drug interaction potential of cannabis products, one must take into consideration the route of administration and dosage of THC and/or CBD. Our report was strengthened by the frequent monitoring of the INR level and our ability to verify medical cannabis product information with the patient’s dispensary. Limitations to our clinical assessment include the following: limited information about the patient’s pain as this was primarily managed outside our facility, lack of THC and CBD serum concentrations (test unavailable at our facility, and the information was not needed to effectively manage the patient’s anticoagulation therapy), and the paucity of published data of dose thresholds of CBD and THC expected to interact with warfarin.

Conclusion

Based on the limited studies and information available, we believe that THC and CBD used by our patient did not impact his warfarin dosing requirements because his THC and CBD doses were too low to inhibit CYP enzymes responsible for warfarin metabolism. This case provides additional evidence that THC interacts with warfarin in a dose-dependent manner. In our patient case, 0.3–0.925 mg THC and 5.3–5.925 mg CBD administered via the oromucosal route daily for up to 8 months did not impact warfarin’s metabolism or result in any significant changes in INR levels.

As legalization of cannabis continues to expand, the number of people using cannabis products will increase. Healthcare professionals must be diligent in asking about cannabis use, which includes use of CBD-only products and cannabis products (which will contain both THC and CBD compounds). If the patient confirms use, the health care professional must also attempt to determine the THC and CBD amounts in the products, the frequency of use, and route of administration. All of these considerations will help the healthcare professional to make informed decisions about the potential for drug-drug interactions. Finally, we must note that the ability to determine the THC and CBD amounts in a medical cannabis product will vary by state, as wide variability exists in state reporting requirements of THC and CBD amounts.

Availability of data and materials

Not applicable; no author-generated data are described in this manuscript.

Can you consume CBD gummies along with Warfarin?

Warfarin is an anticoagulant that helps to prevent blood clot formation. It is mainly used to treat deep vein thrombosis, myocardial infarction, pulmonary embolism, etc.

On the other hand, CBD is present in marijuana and hemp plants to help treat insomnia, inflammation, anxiety, and more. Since Warfarin is a blood thinner, one of the most commonly asked questions is if it can be mixed with Sunday Scaries CBD gummies . We will discuss it thoroughly in the coming sections.

What is the impact of CBD on the body?

Many people use CBD oil because of the benefits that it has to offer. CBD is obtained from cannabis plants and can have numerous positive impacts on the body. Hemp-based oil has been legalized in many places. Nonetheless, the legality of marijuana-based CBD oil will vary significantly .

See also  Is CBD Oil Legal In Ga

Contrary to popular belief, CBD isn’t addictive. Therefore, it can have different impacts on the body. CBD will not get you high and isn’t psychoactive. Nonetheless, CBD does the following benefits:

  • Treats acne
  • Weight management
  • Brain health
  • Relieves pain
  • Healthy for the cardiovascular system
Will CBD gummies interact with medicines?

There are numerous health supplements and herbal products that can interact with CBD. While you start using CBD gummies, you need to understand if they will interact with medicines. As a result, when you introduce CBD to your body, you will need to reduce the use of other drugs.

You should know that not every medicine can be taken together. Therefore, it is advisable to consult professionals before starting the use. The influence of drug interactions will have an essential role in determining if you should be using or not. Furthermore, it would help to consider the dose of medicine, your health condition, and CBD dosage . Talk to your doctor whenever you start using CBD gummies or any medicine.

Will CBD gummies interact with Warfarin?

Yes. Therefore, it is advisable not to consume CBD gummies with warfarin. The interaction will vary depending on the dosage of consumption. Since it can pose a high risk, you shouldn’t start usage unless you’re advised. The combination will have a slow impact on the body.

It will break down and eliminate warfarin from the body. As a result, your body will increase serum levels. If the serum concentration in your body increases, you will likely experience some side effects. These side effects require immediate medical conditions, or they can cause internal bleeding.

How do CBD gummies interact with Warfarin?

The CBD interaction with Warfarin usually happens in two ways. These include:

This condition happens when two medicines will require the same enzyme for metabolism. As a result, both will start competing against each other to get the enzyme. The metabolic inhibitor will lead to slower elimination. As a result, it will slow down the metabolism of both drugs.

The metabolism of Warfarin happens through CYP459 enzymes. However, the CYP2C19 and CYP3A4 enzymes play a significant part, whereas those with lesser impact include CYP2D6, CYP3A5, and CYP1A22.

These enzymes play an essential role in the metabolism of CBD as well. Therefore, when these two medicines are taken together, CBD gummies overpowers Warfarin. As a result, the body may notice the excessive accumulation of Warfarin, which may eventually lead to various side effects, mainly headache and bruising.

While the previous impact slows down, it can also lead to an increased effect that can be dangerous. This condition occurs because two drugs will have the same impact on the body. If these two medicines are used together, they will act upon the same receptor, causing directional impact.

Since CBD gummies are overpowering, it will take over Warfarin, thereby ensuring the latter’s accumulation in the body. When Warfarin stays in your body for a long time, it will become potent, increasing the risk of side effects.

Should you take CBD gummies with Warfarin?

No. As suggested above, CBD gummies and Warfarin can pave the way for a host of side effects. Over-accumulation of Warfarin in the body will cause most of the side effects. As a result, the process of blood clotting will become slow. Therefore, people will be prone to bleeding easily, increasing the risk of bruising and internal bleeding. Many people may also experience hemorrhage, even due to minor injuries.

Medical professionals recommend never to take these two medicines together. You should see a doctor before you start using CBD gummies with Warfarin. The same may be followed when using any other blood-thinning medicine. It is often advisable to start with a minimal dosage of CBD gummies.

Can CBD gummies replace Warfarin?

While CBD gummies are more potent than Warfarin, it shouldn’t be an efficient replacement. Every medicine works differently and can help treat different conditions. CBD as a base will often have an anticoagulant impact, and the anticoagulant impact due to CBD gummies is weaker than that of Warfarin. Furthermore, Warfarin is a prescription drug. Therefore, people can’t use CBD gummies as an alternative unless advised.

What increases the risk of internal bleeding?

However, the treatment of Warfarin can increase the risk of internal bleeding in the initial stages. However, the impact will be severely high for older adults, and it will have the same impact on various blood-thinning medicines.

Common conditions that may contribute to the increased risk of bleeding due to Warfarin usage include kidney problems, alcoholism, liver disease, stroke, blood pressure, gastritis, ulcer, and peptic disorders. Genetic factors are also an important point to consider. The doctor will be able to recommend genetic tests that can eventually help you understand what the best Warfarin dosage is.

Conclusion

If you plan to use CBD gummies and Warfarin together, you need to be familiar with the side effects. Our body will absorb CBD with the help of CPY450, which also impacts the absorption of Warfarin. Many times consistent usage can also increase the risk of fatality.

Before using any product, you must seek medical advice. The cbd cherry gummies can prove to be highly beneficial. However, it is always advisable to be familiar with the dosage quantity. Furthermore, it is advisable to go for only the tested products.

How useful was this post?

Click on a star to rate it!

Average rating 3 / 5. Vote count: 1

No votes so far! Be the first to rate this post.